iECURE, inc., a gene-editing company spun out of Penn and co-founded by James Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director’s Professor at Penn Medicine, reported preliminary findings from the first infant dosed with its in vivo gene editing candidate ECUR-506 in an ongoing phase 1/2 clinical trial in the genetic disorder Ornithine Transcarbamylase (OTC) deficiency.
Read more here and here.